HomeCompareAEZS vs JEPQ

AEZS vs JEPQ: Dividend Comparison 2026

AEZS yields 34.97% · JEPQ yields 11.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AEZS wins by $130.8K in total portfolio value
10 years
AEZS
AEZS
● Live price
34.97%
Share price
$5.72
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$175.6K
Annual income
$26,494.15
Full AEZS calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.10%
Share price
$55.52
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.8K
Annual income
$2,152.59
Full JEPQ calculator →

Portfolio growth — AEZS vs JEPQ

📍 AEZS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAEZSJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AEZS + JEPQ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AEZS pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AEZS
Annual income on $10K today (after 15% tax)
$2,972.03/yr
After 10yr DRIP, annual income (after tax)
$22,520.03/yr
JEPQ
Annual income on $10K today (after 15% tax)
$943.83/yr
After 10yr DRIP, annual income (after tax)
$1,829.70/yr
At 15% tax rate, AEZS beats the other by $20,690.33/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AEZS + JEPQ for your $10,000?

AEZS: 50%JEPQ: 50%
100% JEPQ50/50100% AEZS
Portfolio after 10yr
$110.2K
Annual income
$14,323.36/yr
Blended yield
13.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on AEZS right now

AEZS
Analyst Ratings
4
Buy
2
Hold
1
Sell
Consensus: Buy
Altman Z
0.3
Piotroski
1/9
JEPQ
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AEZS buys
0
JEPQ buys
0
No recent congressional trades found for AEZS or JEPQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAEZSJEPQ
Forward yield34.97%11.10%
Annual dividend / share$2.00$6.16
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$175.6K$44.8K
Annual income after 10y$26,494.15$2,152.59
Total dividends collected$126.6K$16.3K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: AEZS vs JEPQ ($10,000, DRIP)

YearAEZS PortfolioAEZS Income/yrJEPQ PortfolioJEPQ Income/yrGap
1← crossover$14,197$3,496.50$11,930$1,110.39+$2.3KAEZS
2$19,829$4,639.08$14,133$1,224.34+$5.7KAEZS
3$27,273$6,055.84$16,632$1,340.46+$10.6KAEZS
4$36,967$7,784.29$19,454$1,457.97+$17.5KAEZS
5$49,415$9,860.73$22,626$1,576.08+$26.8KAEZS
6$65,193$12,318.97$26,175$1,694.09+$39.0KAEZS
7$84,946$15,189.12$30,133$1,811.32+$54.8KAEZS
8$109,388$18,496.47$34,531$1,927.17+$74.9KAEZS
9$139,306$22,260.50$39,403$2,041.08+$99.9KAEZS
10$175,552$26,494.15$44,787$2,152.59+$130.8KAEZS

AEZS vs JEPQ: Complete Analysis 2026

AEZSStock

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

Full AEZS Calculator →

JEPQETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this AEZS vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AEZS vs SCHDAEZS vs JEPIAEZS vs OAEZS vs KOAEZS vs MAINAEZS vs XYLDAEZS vs QYLDAEZS vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.